Close Navigation
About Arix
Strategy
Overview
Investment Case
News
Results
Documents
Events
Calendar
Analysts
Stock info
Contact
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
10th July 2020
Useful Tools
Download, print or share this article
Print Article
Email Article
Save Article
Share Article
Twitter
LinkedIn
Facebook